The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesThe role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemiaPharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple MechanismsBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaTargeting RTK Signaling Pathways in CancerPI3K isoform-selective inhibitors: next-generation targeted cancer therapiesPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHLStromal Fibroblast in Age-Related Cancer: Role in Tumorigenesis and Potential as Novel Therapeutic TargetTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateThe B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignanciesIbrutinib (PCI-32765) in chronic lymphocytic leukemiaIdelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular LymphomaThe outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyMolecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemiaNovel agents in mantle cell lymphomaBeyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphomaHow will B-cell-receptor-targeted therapies change future CLL therapy?The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibSignal transduction in the chronic leukemias: implications for targeted therapiesCharacterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.The therapeutic potential of targeting the PI3K pathway in pediatric brain tumorsChronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentB-cell receptor signalling and its crosstalk with other pathways in normal and malignant cellsIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaDasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphomaTargeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyPI3K and cancer: lessons, challenges and opportunitiesIdelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaThe Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Targeting the phosphoinositide 3-kinase pathway in hematologic malignanciesMantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis
P2860
Q26748775-86E7229B-705C-40B3-A908-DEA5FB76FFE7Q26751006-DF85944C-4398-4295-9BB7-B6CAEBDF2F4DQ26751444-FBCF3A35-8E5F-494D-9256-FFF8F72B136FQ26765624-AAAC4002-F46E-4926-BF1F-6DF877B95F72Q26775506-A33477CA-8449-49BC-B622-D96F76C633EEQ26781278-8B7B8013-EB9B-4F81-A1FF-B92A4256B140Q26781294-886028CF-36B1-4124-B413-ECB029ED55C6Q26782633-619813F8-2F6E-41E0-9D59-F253277E8BD2Q26795504-57EF16BA-44A9-4E9C-A2B7-D03BA7C914E8Q26797288-ADF9AC44-64B4-4E1E-AF69-120FA32A541AQ26798062-1D5FF154-0423-4926-BE0E-67AEF8E482E3Q26822700-0B95E098-FA89-4A67-B33F-1C652C6F6644Q26852328-3DD12D07-2C80-45B6-B8AF-D6F860BA0803Q26865645-284B4BAD-97B3-455F-B6CB-80B236274CFAQ26865760-45831EFB-1186-40D6-B074-4E8E94F0607FQ27006068-E10B0086-0708-4C18-B9FF-6E506FF77244Q27011763-A79BA868-CA57-4830-B334-A903AD5E4B56Q27013785-7CAE3C09-F9DD-4C94-BB18-0DA45046E4C4Q27024187-E728917E-8280-47DE-8275-0E749CBA2D78Q27024411-E15F73C1-3DD3-4273-9CF7-49E80BD0E594Q27025812-D24CA74F-F224-4DB3-BD36-77C419240BA8Q27026031-26A5BF7E-5A23-4F3E-AFFB-1944AACC3C0AQ27304652-88C7F1BC-13E3-407A-9333-CA66B4DAFDC6Q27687567-9FE1477C-08EF-4970-8CAE-09A20081E5DEQ28070264-8ECF6D67-A1C5-4015-99A7-E8C68D2DAC37Q28082086-4F4F6ABC-4063-4E70-9DFC-8249D3789BE0Q28245018-9AE25561-26FE-42D1-B245-98867C3A80DEQ28306347-610E7B7C-2F47-4BE4-8AAD-EF2719E05F19Q28484839-4DE9803A-CD9E-46CE-B28E-D75F03E5632FQ28649793-437C4886-F8D3-41F4-9C62-FB7FCB346BF7Q29248893-B5800AC3-12F1-4260-849D-3317650462E0Q30080017-3D1B22C3-FA92-4F12-BEB8-3CFCF7B920DEQ30365752-75842DBD-F7FB-4E3F-B50A-ED0BC4958599Q31070331-E94F6D34-CC85-4C34-B4CF-F63439827A17Q33413834-3FD8426A-E3E0-4EDD-B944-064CCE763E79Q33558141-EEA7353E-72EB-42D9-87FF-F72C7751DCE4Q33586239-554D7AC6-7434-457C-8480-E1AE580B61DCQ33690142-8717BB1A-A7CB-4A48-92FD-FE7235AF3EE4Q33749652-AAD7C9F4-8418-49EA-BAF9-E957F92E7FE0Q33785941-77524251-FAD8-4B41-991A-A5E6CF6D799C
P2860
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.
@en
The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.
@nl
type
label
The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.
@en
The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.
@nl
prefLabel
The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.
@en
The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P50
P1433
P1476
The phosphoinositide 3'-kinase ...... chronic lymphocytic leukemia.
@en
P2093
Brian J Lannutti
Jan A Burger
Julia Hoellenriegel
Langdon L Miller
Mariela Sivina
Neill Giese
Sarah A Meadows
P2860
P304
P356
10.1182/BLOOD-2011-05-352492
P407
P577
2011-07-29T00:00:00Z